Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pediatrics/Neonatology | Neurology | Psychiatry/Psychology | Family Medicine
Autism Clinical Trials
A listing of Autism medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Dothan : Forest Investigative Site 068
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Arizona
Phoenix : Southwest Autism Research and Resource Center Updated
A Trial of CM-AT in Children With Autism- Open Label Extension Study
Phoenix : Forest Investigative Site 005
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Tucson : Forest Investigative Site 055
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Arkansas
Little Rock : Forest Investigative Site 077
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Little Rock : Woodland International Research Group, Inc.
Lurasidone Pediatric Pharmacokinetics Study
Springdale : Woodland Northwest Research, LLC
Lurasidone Pediatric Pharmacokinetics Study
California
Glendale : Forest Investigative Site 054
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Imperial : Forest Investigative Site 109
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Los Angeles : Forest Investigative Site 096
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Murrietta : World Wide Research Centers Inc.
Lurasidone Pediatric Pharmacokinetics Study
San Francisco : University of California, San Francisco Updated
A Trial of CM-AT in Children With Autism- Open Label Extension Study
View More »
San Francisco : Forest Investigative Site 021
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Santa Ana : Forest Investigative Site 026
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Colorado
Boulder : Forest Investigative Site 078
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Centennial : Forest Investigative Site 073
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
District of Columbia
Washington : Forest Investigative Site 052
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Florida
Bradenton : Forest Investigative Site 075
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Ft. Lauderdale : Segal Institute for Clinical Research
Lurasidone Pediatric Pharmacokinetics Study
Gainesville : Forest Investigative Site 080
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Jacksonville : Forest Investigative Site 117
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Maitland : Forest Investigative Site 065
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
View More »
Miami : Forest Investigative Site 118
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Oakland Park : Forest Investigative Site 085
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orange City : Lake Mary Pediatrics Updated
A Trial of CM-AT in Children With Autism- Open Label Extension Study
Orange City : Forest Investigative Site 115
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orlando : Forest Investigative Site 114
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orlando : Forest Investigative Site 125
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orlando : Forest Investigative Site 062
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
South Miami : Miami Children's Hospital
Lurasidone Pediatric Pharmacokinetics Study
Tampa : Forest Investigative Site 067
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Wellington : Forest Investigative Site 101
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Georgia
Illinois
Libertyville : Forest Investigative Site 102
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Naperville : Forest Investigative Site 023
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Indiana
Evansville : Forest Investigative Site 082
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Fort Wayne : Forest Investigative Site 123
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Indianapolis : Forest Investigative Site 084
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Indianapolis : Forest Investigative Site 056
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Kansas
Wichita : Forest Investigative Site 106
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Kentucky
Lexington : University of Kentucky Chandler Medical Center
Children: Evaluating the Validity of Intelligence Testing for Children with Autism Spectrum Disorders
View More »
Louisville : Forest Investigative Site 061
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Owensboro : Forest Investigative Site 074
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Louisiana
Lake Charles : Lake Charles Clinical Trials
Safety and Tolerability Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
View More »
Lake Charles : Forest Investigative Site 095
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Maryland
Baltimore : Johns Hopkins Bayview Medical Center Updated
Participate in Brain Research on High Functioning Autism
View More »
Rockville : Forest Investigative Site 086
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Massachusetts
Boston : Massachusetts General Hospital
A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders
Boston : Children's Hospital Boston
SynapDx Autism Gene Expression Analysis Study
Newton : Forest Investigative Site 059
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Springfield : Forest Investigative Site 108
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Nebraska
Lincoln : Forest Investigative Site 097
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Lincoln : Forest Investigative Site 116
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Nevada
Henderson : Forest Investigative Site 130
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Las Vegas : Forest Investigative Site 104
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
New Jersey
Neptune : Forest Investigative Site 136
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Toms River : Forest Investigative Site 127
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
New Mexico
Albuquerque : Forest Investigative Site 107
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Albuquerque : Forest Investigative Site 081
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
New York
North Carolina
Chapel Hill : Forest Investigative Site 072
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Ohio
Avon Lake : Forest Investigative Site 069
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Cleveland : University Hospitals Case Medical Center
Lurasidone Pediatric Pharmacokinetics Study
Columbus : Forest Investigative Site 001
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Oklahoma
Oklahoma City : Forest Investigative Site 019
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Tulsa : Forest Investigative Site 092
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Oregon
Gresham : Forest Investigative Site 053
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Pennsylvania
Johnstown : Forest Investigative Site 132
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
McMurray : Forest Investigative Site 131
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Media : Forest Investigative Site 100
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Philadelphia : CRI Worldwide, LLC
Lurasidone Pediatric Pharmacokinetics Study
Tennessee
Memphis : Forest Investigative Site 090
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Nashville : Forest Investigative Site 057
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Texas
Houston : University of Texas, Houston Updated
A Trial of CM-AT in Children With Autism- Open Label Extension Study
Houston : Forest Investigative Site 051
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
The Woodlands : Forest Investigative Site 070
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Utah
Salt Lake City : CRI Lifetree
The objective of this study is to evaluate the safety and tolerability of memantine in
pediatric (6-12 years old) patients with autism, Asperger’s Disorder, or Pervasive
Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in the follow-up randomized withdrawal study.
View More »
Clinton : Ericksen Research & Development Updated
A Trial of CM-AT in Children With Autism- Open Label Extension Study
Clinton : Forest Investigative Site 028
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Ogden : Forest Investigative Site 141
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orem : Aspen Clinical Research
Lurasidone Pediatric Pharmacokinetics Study
Salt Lake City : Forest Investigative Site 029
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Virginia
Charlottesville : Forest Investigative Site 064
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Norfolk : Forest Investigative Site 113
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Washington
Bothell : Forest Investigative Site 071
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
West Virginia
Charleston : Forest Investigative Site 119
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Wisconsin
Middleton : Forest Investigative Site 063
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Mexico
Tijuana : Instituto de Medicina Regenerativa
Adipose Derived Stem Cell Therapy for Autism
